Emerging Role of Atopic Dermatitis Control Tool in Long-Term Monitoring of Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab

Abstract

Get full access to this article

View all access options for this article.

References

Russo

, Milanesi

, Iannone

, et al. Tuscan Consensus on the diagnosis, treatment and follow up of adult atopic dermatitis. G Ital Dermatol Venereol. 2020; 155(3):253–260.

Russo

, Flori

, Gola

, et al. Severe adult atopic dermatitis: Clinical challenges. Dermatitis, 2020; 31(4):e48–e49.

Hanifin

, Thurston

, Omoto

, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol, 2001; 10:11–18.

Russo

, Cioppa

, Cartocci

, et al. Exploring the relationship between dermatology life quality index, eczema area and severity index, and sleep numerical rating scale and pruritus numerical rating scale in patients with atopic dermatitis treated with dupilumab. Dermatitis, 2023; [Epub ahead of print]; doi: 10.1089/derm.2022.0031.

Simpson

, Eckert

, Gadkari

, et al. Validation of the Atopic Dermatitis Control Tool (ADCT©) using a longitudinal survey of biologic-treated patients with atopic dermatitis. BMC Dermatol, 2019; 19(1):15.

Pariser

, Simpson

, Gadkari

, et al. Evaluating patient-perceived control of atopic dermatitis: design, validation, and scoring of the Atopic Dermatitis Control Tool (ADCT). Curr Med Res Opin, 2020; 36(3):367–376.